Sular and Glipizide drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Sular (nisoldipine) and Glipizide (glipizide). Common drug interactions include mass among females and abdominal pain among males.

The phase IV clinical study analyzes what interactions people have when they take Sular and Glipizide. It is created by eHealthMe based on reports of 48 people who take the same drugs from the FDA, and is updated regularly.

What is Sular?

Sular has active ingredients of nisoldipine. It is often used in high blood pressure. eHealthMe is studying from 1,757 Sular users. Check the latest studies of Sular.

What is Glipizide?

Glipizide has active ingredients of glipizide. It is often used in diabetes. eHealthMe is studying from 64,852 Glipizide users. Check the latest studies of Glipizide.



On Jul, 08, 2026

48 people who take Sular and Glipizide together, and have interactions are studied.

Sular and Glipizide drug interactions.

What are the common drug interactions of Sular and Glipizide, by gender? *:

female:

  1. Mass
  2. Mouth ulceration (mouth ulcers)
  3. Obesity (having too much body fat)
  4. Oropharyngeal pain
  5. Orthopnoea (shortness of breath (dyspnea) when lying down)
  6. Osteoarthritis (a joint disease caused by cartilage loss in a joint)
  7. Osteopenia (a condition where bone mineral density is lower than normal)
  8. Pain in jaw
  9. Plasmacytosis (presence of lots of plasma cells in bone or other tissues)
  10. Purulence (containing pus)

male:

  1. Abdominal pain
  2. Myalgia (muscle pain)
  3. Blood bilirubin increased
  4. Coma (state of unconsciousness lasting more than six hours)
  5. Haemolysis (breaking open of red blood cells and the release of haemoglobin into the surrounding fluid)
  6. Overdose
  7. Renal failure (kidney dysfunction)
  8. Respiratory failure (inadequate gas exchange by the respiratory system)
  9. Acidosis (build-up of carbon dioxide in the blood)
  10. Acute stress disorder

What are the common drug interactions of Sular and Glipizide, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Anaemia (lack of blood)
  2. Anxiety
  3. Asthenia (weakness)
  4. Cardiac failure congestive
  5. Device dislocation
  6. Dystonia (abnormal muscle tone)
  7. Emotional disorder
  8. Extrapyramidal disorder (involuntary muscle spasms in the face and neck)
  9. Malaise (a feeling of general discomfort or uneasiness)
  10. Nausea (feeling of having an urge to vomit)

30-39:

n/a

40-49:

  1. Anaemia (lack of blood)
  2. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  3. Anxiety
  4. Aortic arteriosclerosis (hardening of the aortic arteries)
  5. Aortic disorder
  6. Aortic valve incompetence
  7. Aphthous stomatitis (mouth ulcer)
  8. Asthenia (weakness)
  9. Asthma
  10. Atelectasis (partial or complete collapse of the lung)

50-59:

  1. Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
  2. Drug ineffective
  3. Gastric cancer (stomach cancer)
  4. Linitis plastica
  5. Renal failure (kidney dysfunction)
  6. Transient ischaemic attack (a transient episode of neurologic dysfunction caused by ischemia (loss of blood flow))
  7. Bradycardia (abnormally slow heart action)
  8. Hypotension (abnormally low blood pressure)
  9. Renal impairment (severely reduced kidney function)
  10. Coma (state of unconsciousness lasting more than six hours)

60+:

  1. Pyrexia (fever)
  2. Urinary tract infection
  3. Aortic valve incompetence
  4. Asthenia (weakness)
  5. Back pain
  6. Bladder cancer
  7. Bone disorder
  8. Bone pain
  9. Chest pain
  10. Chills (felling of cold)

What are the existing conditions these people have? *

  1. Multiple Myeloma (cancer of the plasma cells): 13 people, 27.08%
  2. Type 2 Diabetes: 4 people, 8.33%
  3. Idiopathic Thrombocytopenic Purpura (bleeding disorder in which the immune system destroys platelets, which are necessary for normal blood clotting): 4 people, 8.33%
  4. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Sular and Glipizide?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Sular and Glipizide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Sular:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Glipizide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Sular and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Glipizide and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on nisoldipine and glipizide (the active ingredients of Sular and Glipizide, respectively), and Sular and Glipizide (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: